Back to results
US 2012/0252734 A1Published application
Inhibitors of antigen presentation by mhc class ii molecules
AssigneeProvid Pharmaceuticals, Inc.
InventorsGary Lee Olson, Charles Michael Cook, Christopher Raymond Self
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.
Claims20
A compound, wherein the compound is:
- ENPVVHFFKNI;
- AcVHFFKNI;
- AcIHFFKNI;
- AcVRFFKNI;
- AcVHPFKNI;
- AcVHFFPNI;
- AcVHFFKTI;
- AcVRFANI;
- AcVRPFS;
- AcVRLFANI;
- AcVVHFFKNI;
- AcVTFFKNI;
- AcVH(N-Me Ala)FKNI;
- AcVHA(N-Me Ala)-F—(N-Me Ala)N;
- AcVHFVKNI;
- AcVRF(2-NaI)KNI;
- AcVRF(1-NaI)KNI;
- AcVHFFA(N-Me Ala)NI;
- AcVRLFKN;
- AcVRF(4′-Pyridyl Ala)KNI;
- AcVRAFAN;
- AcVRA(O-Benzyl Ser)KNI;
- Ac(Tic)FKNI;
- AcVR(Tic)FKNI;
- Ac(Cpg)RFFKNI;
- AcVHSFSN;
- AcVRF(3′ Cyano Phe)KNI;
- AcVR(Tiq)FKNI;
- Ac(Tiq)FKNI;
- AcVVRFFK;
- AcVRFF(homo Pro)NI;
- Ac(Tic)FKNI;
- Ac(Cpg)R(Tic)FKNI;
- AcVR(homo Pro)FKNI;
- AcVRFFK;
- AcVKFFKNI;
- AcV(Orn)FFKNI;
- AcV(N′ Alloc Dab)FFKNI;
- Ac(Cha)RFFKNI;
- Ac(2′ Furanyl Ala)RFFKNI;
- Ac(2′ Thienyl Ala)RFFKNI;
- AcVR(2′ Furanyl Ala)FKNI;
- AcVR(2′ Thienyl Ala)FKNI;
- AcVRAFKNI;
- Benzoyl-VRFFK;
- Isobutanoyl-VRFFK;
- Butanoyl-VRFFK;
- IsoValeroyl-VRFFK;
- Ac(Cpg)R(Tic)F(homo Pro);
- AcVVRFF;
- 3-(Imadazoyl-4-yl)propionyl-VRFFK;
- Ac(Chg)RFFKNI;
- AcVRFF(Dap)NI;
- AcV(Dab)FFKNI;
- AcVVAGFKNI;
- AcVAGFKNI;
- AcV(Dap)FFKNI;
- AcVRFF;
- AcVRF(3′ phenoxy Phe)KNI;
- AcVVKF(3′ Methylamino Phe) K;
- AcFRFFKNI;
- AcVRFFK(beta Ala)I;
- AcV('-amino-1′-carboxymethyl-pyridin-2′-one)FKNI;
- Ac(Idg)RFFKNI;
- AcAVRFFK;
- AcAVHFFKNI;
- AcV(2′ Furanyl Ala)FFKNI;
- AcV(2′ Thienyl Ala)FFKNI;
- AcVVKF(3′ Cyano Phe)K;
- Ac(Phg)RFFKNI;
- AcIR(Tic)F(homo Pro);
- AcLRFFKNI;
- AcVR(Phg)FKNI;
- AcVVRF(3′ phenoxy Phe)K;
- AcVRF(Phg)KNI;
- AcVRFFK(beta Ala);
- AcVVRFFK(beta Ala);
- Ac(Chg)VRFFK;
- Ac(Chg)RF(4′-Indolyl Ala)KNI
- AcVRF(3′-Carbazolyl Ala)KNI;
- Ac(Cpg)-NHNH(COCH2CH(Ph)CO)KNI;
- AcVRF(3′-amino Phe)KNI;
- AcWRFFKNI;
- AcV(ω, ω) dimethyl Lys)FFKNI;
- AcV(Chg)RFFK;
- AcV(nor Arg)FFKNI;
- AcVRF(3-Acetylamino Phe)KNI;
- Ac(Chg)R(Tic)F(4′-hydroxy Pro);
- Ac(Chg)R(Tic);
- AcVKFFENI;
- AcVRIFKNI;
- Ac(Cpg)-NHNH(COCH2CH(Ph)CO)FKNI;
- Ac(Chg)R(Tic)-(3′-Carbazolyl Ala);
- Ac(Chg)R(Tic)F(homo Pro);
- Ac(Idg)R(Tic)FK;
- AcV(Idg)R(Tic)FK;
- AcV(Chg)R(Tic)F;
- AcV(Chg)RFFK;
- Ac(Chg)R(Tic)-(3′-Carbazolyl Ala)G;
- AcV(Chg)R(Tic)-(3′-Carbazolyl Ala)G;
- AcVVRF(3′-Acetylaminomethyl Phe);
- AcVVRF(3′-Methylsulphonyl aminomethyl Phe);
- (2,6-Dimethyl Benzoyl)-VRFFK;
- AcV(homo Arg)FFKNI;
- Ac(Cpg)-NHNH(COCH2CH(Ph)CO)-(4′-Indolyl Ala)K;
- or a pharmaceutically acceptable salt thereof.
103 more elements
Dependencies are inferred from the claim text.